{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T08:19:27Z","timestamp":1766391567858,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K07150","22H04281"],"award-info":[{"award-number":["20K07150","22H04281"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s00280-023-04569-w","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T17:02:21Z","timestamp":1690477341000},"page":"315-324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of polymorphisms in pregnane X receptor and ABC transporters on afatinib in Japanese patients with non-small cell lung cancer: pharmacogenomic\u2013pharmacokinetic and exposure\u2013response analysis"],"prefix":"10.1007","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1389-435X","authenticated-orcid":false,"given":"Hayato","family":"Yokota","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Asano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahide","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsutoshi","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7120-2425","authenticated-orcid":false,"given":"Masatomo","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"key":"4569_CR1","doi-asserted-by":"publisher","first-page":"4702","DOI":"10.1038\/onc.2008.109","volume":"27","author":"D Li","year":"2008","unstructured":"Li D, Ambrogio L, Shimamura T et al (2008) BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27:4702\u20134711. https:\/\/doi.org\/10.1038\/onc.2008.109","journal-title":"Oncogene"},{"key":"4569_CR2","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1124\/jpet.112.197756","volume":"343","author":"F Solca","year":"2012","unstructured":"Solca F, Dahl G, Zoephel A et al (2012) Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 343:342\u2013350. https:\/\/doi.org\/10.1124\/jpet.112.197756","journal-title":"J Pharmacol Exp Ther"},{"key":"4569_CR3","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1200\/jco.2012.44.2806","volume":"31","author":"LV Sequist","year":"2013","unstructured":"Sequist LV, Yang JC-H, Yamamoto N et al (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31:3327\u20133334. https:\/\/doi.org\/10.1200\/jco.2012.44.2806","journal-title":"J Clin Oncol"},{"key":"4569_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/s1470-2045(13)70604-1","volume":"15","author":"Y-L Wu","year":"2014","unstructured":"Wu Y-L, Zhou C, Hu C-P et al (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 15:213\u2013222. https:\/\/doi.org\/10.1016\/s1470-2045(13)70604-1","journal-title":"Lancet Oncol"},{"key":"4569_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/s1470-2045(14)71173-8","volume":"16","author":"JC-H Yang","year":"2015","unstructured":"Yang JC-H, Wu Y-L, Schuler M et al (2015) Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 16:141\u2013151. https:\/\/doi.org\/10.1016\/s1470-2045(14)71173-8","journal-title":"Lancet Oncol"},{"key":"4569_CR6","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1111\/cas.12723","volume":"106","author":"T Kato","year":"2015","unstructured":"Kato T, Yoshioka H, Okamoto I et al (2015) Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3. Cancer Sci 106:1202\u20131211. https:\/\/doi.org\/10.1111\/cas.12723","journal-title":"Cancer Sci"},{"key":"4569_CR7","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/s1470-2045(16)30033-x","volume":"17","author":"K Park","year":"2016","unstructured":"Park K, Tan E-H, O\u2019Byrne K et al (2016) Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol 17:577\u2013589. https:\/\/doi.org\/10.1016\/s1470-2045(16)30033-x","journal-title":"Lancet Oncol"},{"key":"4569_CR8","doi-asserted-by":"publisher","first-page":"103305","DOI":"10.1016\/j.critrevonc.2021.103305","volume":"160","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Cheng B, Chen Z et al (2021) Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: a systematic review and network meta-analysis. Crit Rev Oncol Hematol 160:103305. https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103305","journal-title":"Crit Rev Oncol Hematol"},{"key":"4569_CR9","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00280-014-2403-2","volume":"73","author":"M Freiwald","year":"2014","unstructured":"Freiwald M, Schmid U, Fleury A et al (2014) Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors. Cancer Chemother Pharmacol 73:759\u2013770. https:\/\/doi.org\/10.1007\/s00280-014-2403-2","journal-title":"Cancer Chemother Pharmacol"},{"key":"4569_CR10","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3390\/cancers10100384","volume":"10","author":"AM Hopkins","year":"2018","unstructured":"Hopkins AM, Nguyen A-M, Karapetis CS et al (2018) Risk factors for severe diarrhea with an afatinib treatment of non-small cell lung cancer: a pooled analysis of clinical trials. Cancers (Basel) 10:384. https:\/\/doi.org\/10.3390\/cancers10100384","journal-title":"Cancers (Basel)"},{"key":"4569_CR11","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.resinv.2016.07.003","volume":"54","author":"Y Wada","year":"2016","unstructured":"Wada Y, Koyama S, Kuraishi H et al (2016) Clinical analysis of patients treated with afatinib for advanced non-small cell lung cancer: a Nagano Lung Cancer Research Group observational study. Respir Investig 54:462\u2013467. https:\/\/doi.org\/10.1016\/j.resinv.2016.07.003","journal-title":"Respir Investig"},{"key":"4569_CR12","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s40262-013-0091-4","volume":"52","author":"S Wind","year":"2013","unstructured":"Wind S, Schmid M, Erhardt J et al (2013) Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours. Clin Pharmacokinet 52:1101\u20131109. https:\/\/doi.org\/10.1007\/s40262-013-0091-4","journal-title":"Clin Pharmacokinet"},{"key":"4569_CR13","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3390\/biology10101054","volume":"10","author":"H Yokota","year":"2021","unstructured":"Yokota H, Sato K, Sakamoto S et al (2021) Relationship between plasma concentrations of afatinib and the onset of diarrhea in patients with non-small cell lung cancer. Biology (Basel) 10:1054. https:\/\/doi.org\/10.3390\/biology10101054","journal-title":"Biology (Basel)"},{"key":"4569_CR14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40262-016-0440-1","volume":"56","author":"S Wind","year":"2017","unstructured":"Wind S, Schnell D, Ebner T et al (2017) Clinical pharmacokinetics and pharmacodynamics of afatinib. Clin Pharmacokinet 56:235\u2013250. https:\/\/doi.org\/10.1007\/s40262-016-0440-1","journal-title":"Clin Pharmacokinet"},{"key":"4569_CR15","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s00280-017-3378-6","volume":"80","author":"J Sato","year":"2017","unstructured":"Sato J, Morikawa N, Chiba R et al (2017) Case series on the association between blood levels and side effects of afatinib maleate. Cancer Chemother Pharmacol 80:545\u2013553. https:\/\/doi.org\/10.1007\/s00280-017-3378-6","journal-title":"Cancer Chemother Pharmacol"},{"key":"4569_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2019.05.013","volume":"134","author":"H Hayashi","year":"2019","unstructured":"Hayashi H, Iihara H, Hirose C et al (2019) Effects of pharmacokinetics-related genetic polymorphisms on the side effect profile of afatinib in patients with non-small cell lung cancer. Lung Cancer 134:1\u20136. https:\/\/doi.org\/10.1016\/j.lungcan.2019.05.013","journal-title":"Lung Cancer"},{"key":"4569_CR17","doi-asserted-by":"publisher","first-page":"18202","DOI":"10.1038\/s41598-019-54804-9","volume":"9","author":"K Nakao","year":"2019","unstructured":"Nakao K, Kobuchi S, Marutani S et al (2019) Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer. Sci Rep 9:18202. https:\/\/doi.org\/10.1038\/s41598-019-54804-9","journal-title":"Sci Rep"},{"key":"4569_CR18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1080\/00498254.2019.1610585","volume":"50","author":"Y Tan","year":"2020","unstructured":"Tan Y, Cao K, Ren G et al (2020) Effects of the ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of afatinib in healthy Chinese volunteers. Xenobiotica 50:237\u2013243. https:\/\/doi.org\/10.1080\/00498254.2019.1610585","journal-title":"Xenobiotica"},{"key":"4569_CR19","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.21873\/invivo.11922","volume":"34","author":"R Sogawa","year":"2020","unstructured":"Sogawa R, Nakashima C, Nakamura T et al (2020) Association of genetic polymorphisms with afatinib-induced diarrhoea. In Vivo 34:1415\u20131419. https:\/\/doi.org\/10.21873\/invivo.11922","journal-title":"In Vivo"},{"key":"4569_CR20","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.3390\/biom11081142","volume":"11","author":"A Skandalaki","year":"2021","unstructured":"Skandalaki A, Sarantis P, Theocharis S (2021) Pregnane X receptor (PXR) polymorphisms and cancer treatment. Biomolecules 11:1142. https:\/\/doi.org\/10.3390\/biom11081142","journal-title":"Biomolecules"},{"key":"4569_CR21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00280-014-2494-9","volume":"74","author":"W Zhuo","year":"2014","unstructured":"Zhuo W, Hu L, Lv J et al (2014) Role of pregnane X receptor in chemotherapeutic treatment. Cancer Chemother Pharmacol 74:217\u2013227. https:\/\/doi.org\/10.1007\/s00280-014-2494-9","journal-title":"Cancer Chemother Pharmacol"},{"key":"4569_CR22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.taap.2004.10.012","volume":"204","author":"EM Leslie","year":"2005","unstructured":"Leslie EM, Deeley RG, Cole SP (2005) Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204:216\u2013237. https:\/\/doi.org\/10.1016\/j.taap.2004.10.012","journal-title":"Toxicol Appl Pharmacol"},{"key":"4569_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/FTD.0b013e31829dabbc","volume":"36","author":"M Miura","year":"2014","unstructured":"Miura M, Sato K, Miura H et al (2014) A limited sampling strategy for estimation of the area under the plasma concentration-time curve of gefitinib. Ther Drug Monit 36:24\u201329. https:\/\/doi.org\/10.1097\/FTD.0b013e31829dabbc","journal-title":"Ther Drug Monit"},{"key":"4569_CR24","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/jso.20774","volume":"96","author":"L Wu","year":"2007","unstructured":"Wu L, Xu X, Shen J et al (2007) MDR1 gene polymorphisms and risk of recurrence in patients with hepatocellular carcinoma after liver transplantation. J Surg Oncol 96:62\u201368. https:\/\/doi.org\/10.1002\/jso.20774","journal-title":"J Surg Oncol"},{"key":"4569_CR25","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/bf02981939","volume":"73","author":"H Tanaka","year":"2001","unstructured":"Tanaka H, Imamura N, Oguma N et al (2001) Acute myelogenous leukemia with PIG-A gene mutation evolved from aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome. Int J Hematol 73:206\u2013212. https:\/\/doi.org\/10.1007\/bf02981939","journal-title":"Int J Hematol"},{"key":"4569_CR26","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1067\/mcp.2001.114164","volume":"69","author":"I Cascorbi","year":"2001","unstructured":"Cascorbi I, Gerlof T, Johne A et al (2001) Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69:169\u2013174. https:\/\/doi.org\/10.1067\/mcp.2001.114164","journal-title":"Clin Pharmacol Ther"},{"key":"4569_CR27","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1124\/dmd.104.001628","volume":"33","author":"D Kobayashi","year":"2005","unstructured":"Kobayashi D, Ieiri I, Hirota T et al (2005) Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos 33:94\u2013101. https:\/\/doi.org\/10.1124\/dmd.104.001628","journal-title":"Drug Metab Dispos"},{"key":"4569_CR28","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1097\/01.tp.0000235533.29300.e7","volume":"82","author":"M Naesens","year":"2006","unstructured":"Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y (2006) Multidrug resistance protein 2 genetic polymorphisms infuence mycophenolic acid exposure in renal allograft recipients. Transplantation 82:1074\u20131084. https:\/\/doi.org\/10.1097\/01.tp.0000235533.29300.e7","journal-title":"Transplantation"},{"key":"4569_CR29","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1053\/j.gastro.2005.12.008","volume":"130","author":"MM Dring","year":"2006","unstructured":"Dring MM, Goulding CA, Trimble VI et al (2006) The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology 130:341\u2013348. https:\/\/doi.org\/10.1053\/j.gastro.2005.12.008","journal-title":"Gastroenterology"},{"key":"4569_CR30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/hep.20516","volume":"41","author":"Y Kimura","year":"2005","unstructured":"Kimura Y, Selmi C, Leung PSC et al (2005) Genetic polymorphisms influencing xenobiotic metabolism and transport in patients with primary biliary cirrhosis. Hepatology 41:55\u201363. https:\/\/doi.org\/10.1002\/hep.20516","journal-title":"Hepatology"},{"key":"4569_CR31","unstructured":"Phan L, Jin Y, Zhang H, et al (2020) National Center for Biotechnology Information, U.S. National Library of Medicine https:\/\/www.ncbi.nlm.nih.gov\/snp\/docs\/gsr\/alfa\/. Accessed 27 Apr 2023"},{"key":"4569_CR32","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1586\/era.13.31","volume":"13","author":"JC-H Yang","year":"2013","unstructured":"Yang JC-H, Reguart N, Barinoff J et al (2013) Diarrhea associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther 13:729\u2013736. https:\/\/doi.org\/10.1586\/era.13.31","journal-title":"Expert Rev Anticancer Ther"},{"key":"4569_CR33","doi-asserted-by":"publisher","first-page":"252","DOI":"10.21037\/tlcr-20-649","volume":"10","author":"M Okajima","year":"2021","unstructured":"Okajima M, Miura S, Watanabe S et al (2021) A prospective phase II study of multimodal prophylactic treatment for afatinib-induced AEs in advanced non-small cell lung cancer (Niigata Lung Cancer Treatment Group 1401). Transl Lung Cancer Res 10:252\u2013260. https:\/\/doi.org\/10.21037\/tlcr-20-649","journal-title":"Transl Lung Cancer Res"},{"key":"4569_CR34","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s00210-015-1150-1","volume":"388","author":"T Reuter","year":"2015","unstructured":"Reuter T, Warta R, Theile D et al (2015) Role of NR1I2 (pregnane X receptor) polymorphisms in head and neck squamous cell carcinoma. Naunyn Schmiedebergs Arch Pharmacol 388:1141\u20131150. https:\/\/doi.org\/10.1007\/s00210-015-1150-1","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"4569_CR35","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.21037\/jtd-21-1649","volume":"14","author":"WC Kwok","year":"2022","unstructured":"Kwok WC, Ho JCM, Tam TCC et al (2022) Serum protein level as a predictor of therapeutic response and adverse effects associated with afatinib use. J Thorac Dis 14:1880\u20131889. https:\/\/doi.org\/10.21037\/jtd-21-1649","journal-title":"J Thorac Dis"},{"key":"4569_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062489","volume":"8","author":"L Gao","year":"2013","unstructured":"Gao L, He Y, Tang J et al (2013) Genetic variants of pregnane X receptor (PXR) and CYP2B6 affect the induction of bupropion hydroxylation by sodium ferulate. PLoS ONE 8:e62489. https:\/\/doi.org\/10.1371\/journal.pone.0062489","journal-title":"PLoS ONE"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04569-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-023-04569-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04569-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T02:02:50Z","timestamp":1692324170000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-023-04569-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["4569"],"URL":"https:\/\/doi.org\/10.1007\/s00280-023-04569-w","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2023,7,27]]},"assertion":[{"value":"10 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or nonfinancial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted according to the principles of the Declaration of Helsinki. The study protocol was approved by the Ethics Committee of Akita University School of Medicine (approval numbers: 790 and 1140).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}